CG Oncology Financial Ratios
NASDAQ: CGONHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
CG Oncology ratio analysis
CG Oncology earned a net margin of -3985.0% in FY 2025, up from -7729.5% a year earlier. Return on equity reached -21.4%, meaning CG Oncology generated -0.21 dollars of profit for every dollar of shareholders' equity. Debt-to-equity stood at 0.00 versus 0.00 the year before, and the current ratio was 24.63.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
CG Oncology financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Price / sales | 799.63 | 1,674.63 | — |
| Price / book | 4.29 | 2.60 | — |
| Operating margin | -4,722.1% | -10,067.3% | -27,180.9% |
| Net margin | -3,985.0% | -7,729.5% | -23,827.0% |
| Free cash flow margin | -3,279.2% | -6,931.3% | -22,391.7% |
| Return on equity (ROE) | -21.4% | -12.0% | — |
| Return on assets (ROA) | -20.3% | -11.7% | -24.4% |
| Debt / equity | 0.00 | 0.00 | — |
| Current ratio | 24.63 | 35.30 | 13.62 |
| Revenue growth | 254.7% | 458.3% | — |